NY-IWBI
26.3.2020 09:02:26 CET | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today that it is standing up a Task Force on reducing the enormous health burden from COVID-19 and other respiratory infections. Its goal is to define the critical role buildings, organizations and communities play in prevention and preparedness, resilience and recovery. The Task Force's work will take a broad approach, considering both new and recurring infectious agents that can affect large populations.
Co-chairing the Task Force are Risa Lavizzo-Mourey, M.D., MBA , former president and CEO of the Robert Wood Johnson Foundation and distinguished professor of population health and health equity at the University of Pennsylvania; Jonathan Fielding, M.D., MPH, MA, MBA , distinguished professor at UCLA in the Fielding School of Public Health and the Geffen School of Medicine and former director and health officer of the Los Angeles County Department of Public Health; Richard Carmona, M.D., MPH, FACS , who was 17th Surgeon General of the United States and is presently distinguished professor at the University of Arizona; and Joseph Allen, DSc, MPH, assistant professor and director of the Healthy Buildings program at Harvard’s T.H. Chan School of Public Health. The task force will include experts from public health, government, academia and philanthropy, as well as the architecture, design and real estate communities.
“IWBI’s work centers on providing evidence-backed solutions that advance better health and well-being in the places and spaces where we spend our lives,” said IWBI Chairman and CEO Rick Fedrizzi. “The creation of this Task Force provides a mechanism to focus on this immediate challenge and collect and apply the expertise and insight of our global community, which includes practicing physicians, environmental and behavioral scientists, leading design practitioners and innovation leaders from global corporations.”
“This task force can help us focus quickly on actionable measures we can take to more fully deliver resources needed to advance a global culture of health that includes everyone,” said Dr. Lavizzo-Mourey.
“This timely effort will mine the scientific literature to identify enhanced opportunities for the built environment to improve population health,” said Dr. Fielding.
Surgeon General Carmona commends IWBI for bringing together global public health thought leaders to focus on optimizing the built environment to prevent, respond to, mitigate and recover from “all hazards” to the United States to include coronavirus. The built environment is an essential element in physical and mental health as well as preventing disease.
“The urgency of action towards mitigating the physical, emotional and economic impacts of this virus and other respiratory infections cannot be overstated,” said Dr. Allen. “Nor can the outsized impact that can occur if we improve our buildings, as well as the policies, protocols and procurement guidelines organizations have in place, so that they work together to protect and improve the health of everyone. This pandemic is the challenge of our time and buildings will play a central role in our response, and ultimate recovery.“
“The aim of the Task Force is twofold,” said IWBI President Rachel Gutter. “First, to identify and develop a set of signature deliverables and resources, including guidelines for individuals, organizations and communities to help them better integrate actionable insights and proven strategies into how they manage both their buildings and their organizations. Second, the Task Force will assess ways in which the WELL Building Standard (WELL) itself can be further strengthened so the system, which touches more than a half-billion square feet of space across 58 countries, can best continue to support prevention and preparedness, resiliency and recovery in this critical moment and into the future.”
Gutter noted that more information about the Task Force and how individuals can raise their hands to get involved can be found here .
“WELL already reflects the massive amount of current health research and data we’ve amassed and integrated since its launch in late 2014,” she said. “But the landscape shifted at the first of the year with the global onset of this virus. We are committed to making sure we share freely everything we’ve learned with our global community and beyond. We owe it to everyone to make sure the comprehensive, evidence-based interventions that we’ve codified in WELL move us in the direction of better health and enhanced resilience for everyone, everywhere.”
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here
.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005121/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
